top of page
Search

Entegris (ENTG): Under-appreciated compounder

  • Writer: Abacus Research
    Abacus Research
  • Feb 3, 2023
  • 1 min read

Entegris is a chemicals and filtration company that just happens to sell into the semiconductor market. We want to be owners of ENTG as it is high-quality, defensive, and an EPS compounder that will out-grow semi volume growth due to trends of increasing purity and material intensity in semis.

  • We think the benefits from the CMC acquisition could surprise on the upside and is not fully appreciated by the market.

  • Financials are poised to improve: EPS growth will accelerate meaningfully in late 2023 driven by revenue growth, high incremental margins, cost saves, and continue into 2025 as debt is paid down.

Potential Upside: $114 (+31%) Sensible Downside: $70 (-20%)


 
 
 

Recent Posts

See All
Axon:

Axon is shifting from selling individual tools to providing an interconnected ecosystem. Hardware like TASERs and cameras now act as "data generators" that feed directly into high-margin software modu

 
 
 
C.H. Robinson

CHRW has been going through significant change, They are retaking market share. The new CEO has transformed the company by bringing in a lean / AI, that has helped CHRW to grow earnings despite strugg

 
 
 
Brookfield (BN):

We initially wrote up BN in Jan 2024, it has increased 70%, so why mention it again? Firstly, we think the fundamentals are as good now as they were 2 yrs ago, with a >15% IRR on offer. BN is not a we

 
 
 

Comments

bottom of page